Genes, Vol. 14, Pages 193: Vitamin D Receptor Gene Polymorphisms Affect Osteoporosis-Related Traits and Response to Antiresorptive Therapy
doslav Omelka
The present study analyzed the effect of vitamin D receptor (VDR) gene polymorphisms (ApaI, TaqI, BsmI, FokI, and Cdx2) on bone mineral density (BMD), biochemical parameters and bone turnover markers, fracture prevalence, and response to three types of antiresorptive therapy (estrogen-progesterone, raloxifene, and ibandronate) in 356 postmenopausal women from Slovakia. Association analysis revealed a significant effect of BsmI polymorphism on lumbar spine BMD, serum osteocalcin (OC), and β-CrossLaps levels. While ApaI and Cdx2 polymorphisms were associated with OC and alkaline phosphatase, Ta...
Source: Genes - January 11, 2023 Category: Genetics & Stem Cells Authors: Vladimira Mondockova Veronika Kovacova Nina Zemanova Martina Babikova Monika Martiniakova Drahomir Galbavy Radoslav Omelka Tags: Article Source Type: research
The clinical effectiveness of denosumab (Prolia ®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
ConclusionIn MPC on HAT, denosumab (relative to placebo) was effective at preventing vertebral fractures and improving BMD at the FN and LS. Moreover, in WBC on AAIT, denosumab (relative to placebo) improved BMD at the FN, LS, TH, and TRO, as well as prevent vertebral fracture. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - January 10, 2023 Category: Orthopaedics Source Type: research
The clinical effectiveness of denosumab (Prolia ®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
ConclusionIn MPC on HAT, denosumab (relative to placebo) was effective at preventing vertebral fractures and improving BMD at the FN and LS. Moreover, in WBC on AAIT, denosumab (relative to placebo) improved BMD at the FN, LS, TH, and TRO, as well as prevent vertebral fracture. (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - January 10, 2023 Category: Orthopaedics Source Type: research
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis : A Living Systematic Review and Network Meta-analysis for the American College of Physicians
CONCLUSION: Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis. Abaloparatide and teriparatide increased WAEs; longer duration bisphosphonate use may increase AFF and ONJ risk though these events were rare.PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42021236220).PMID:36592455 | DOI:10.7326/M22-0684 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 2, 2023 Category: Internal Medicine Authors: Chelsea Ayers Devan Kansagara Brittany Lazur Rongwei Fu Amy Kwon Curtis Harrod Source Type: research
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis : A Living Systematic Review and Network Meta-analysis for the American College of Physicians
CONCLUSION: Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis. Abaloparatide and teriparatide increased WAEs; longer duration bisphosphonate use may increase AFF and ONJ risk though these events were rare.PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42021236220).PMID:36592455 | DOI:10.7326/M22-0684 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 2, 2023 Category: Internal Medicine Authors: Chelsea Ayers Devan Kansagara Brittany Lazur Rongwei Fu Amy Kwon Curtis Harrod Source Type: research
Magnetic Nanoplatform With Novel Potential for the Treatment of Bone Pathologies: Drug Loading and Biocompatibility on Blood and Bone Cells
Magnetic iron oxide nanoparticles (MNPs) coated with citric acid (MG@CA) are proposed as raw materials for the treatment of bone diseases. Citric acid (CA) was selected as coating due to its role in the stabilization of apatite nanocrystals and as a signaling agent for osteoblast activation. Raloxifene (Ral), curcumine (Cur) and methylene blue (MB) were employed as model drugs as therapeutic agents for bone diseases. Characterization of raw and drug loaded nanosystems was conducted in order to elucidate the mechanisms governing interactions between therapeutics and the magnetic platform. Biocompatibility studies wer...
Source: IEE Transactions on NanoBioscience - December 30, 2022 Category: Nanotechnology Source Type: research
Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia
We report here that whereas adult female MIA offspring exhibited cognitive deficits in the form of retarded spatial learning, the administration of raloxifene during adolescence was sufficient in preventing these deficits and resulted in intact performance in the MIA group.PMID:36574844 | DOI:10.1016/j.bbr.2022.114276 (Source: Behavioural Brain Research)
Source: Behavioural Brain Research - December 27, 2022 Category: Neurology Authors: Viktoria Felgel-Farnholz Elizabeth Barroeta Hlusicka Henriette Edemann-Callesen Alexander Garthe Christine Winter Ravit Hadar Source Type: research
Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia
We report here that whereas adult female MIA offspring exhibited cognitive deficits in the form of retarded spatial learning, the administration of raloxifene during adolescence was sufficient in preventing these deficits and resulted in intact performance in the MIA group.PMID:36574844 | DOI:10.1016/j.bbr.2022.114276 (Source: Brain Research)
Source: Brain Research - December 27, 2022 Category: Neurology Authors: Viktoria Felgel-Farnholz Elizabeth Barroeta Hlusicka Henriette Edemann-Callesen Alexander Garthe Christine Winter Ravit Hadar Source Type: research
Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia
We report here that whereas adult female MIA offspring exhibited cognitive deficits in the form of retarded spatial learning, the administration of raloxifene during adolescence was sufficient in preventing these deficits and resulted in intact performance in the MIA group.PMID:36574844 | DOI:10.1016/j.bbr.2022.114276 (Source: Behavioural Brain Research)
Source: Behavioural Brain Research - December 27, 2022 Category: Neurology Authors: Viktoria Felgel-Farnholz Elizabeth Barroeta Hlusicka Henriette Edemann-Callesen Alexander Garthe Christine Winter Ravit Hadar Source Type: research
Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia
We report here that whereas adult female MIA offspring exhibited cognitive deficits in the form of retarded spatial learning, the administration of raloxifene during adolescence was sufficient in preventing these deficits and resulted in intact performance in the MIA group.PMID:36574844 | DOI:10.1016/j.bbr.2022.114276 (Source: Behavioural Brain Research)
Source: Behavioural Brain Research - December 27, 2022 Category: Neurology Authors: Viktoria Felgel-Farnholz Elizabeth Barroeta Hlusicka Henriette Edemann-Callesen Alexander Garthe Christine Winter Ravit Hadar Source Type: research
Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia
We report here that whereas adult female MIA offspring exhibited cognitive deficits in the form of retarded spatial learning, the administration of raloxifene during adolescence was sufficient in preventing these deficits and resulted in intact performance in the MIA group.PMID:36574844 | DOI:10.1016/j.bbr.2022.114276 (Source: Behavioural Brain Research)
Source: Behavioural Brain Research - December 27, 2022 Category: Neurology Authors: Viktoria Felgel-Farnholz Elizabeth Barroeta Hlusicka Henriette Edemann-Callesen Alexander Garthe Christine Winter Ravit Hadar Source Type: research
Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines
AbstractTriple-negative breast cancers (TNBCs) are characterized by a lack of approved targeted therapies and remain a challenge in the clinic. Several overexpressed proteins, including epidermal growth factor receptor (EGFR), have been associated with TNBCs and are considered potential therapeutic targets. However, EGFR inhibitors alone failed to demonstrate a cutting-edge advantage for treating TNBCs over conventional chemotherapies. Studies have shown that selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene also affect TNBC cell viability. The combination of gefitinib and raloxifene was assessed agai...
Source: Medical Oncology - December 9, 2022 Category: Cancer & Oncology Source Type: research
Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay
Antiviral Res. 2022 Nov 23:105473. doi: 10.1016/j.antiviral.2022.105473. Online ahead of print.ABSTRACTTo identify potent antiviral compounds, we introduced a high-throughput screen platform that can rapidly classify hit compounds according to their target. In our platform, we performed a compound screen using a lentivirus-based pseudovirus presenting a spike protein of coronavirus, and we evaluated the hit compounds using an amplified luminescence proximity homogeneous assay (alpha) test with purified host receptor protein and the receptor binding domain of the viral spike. With our screen platform, we were able to identi...
Source: Antiviral Research - November 26, 2022 Category: Virology Authors: Kwiwan Jeong JuOae Chang Sun-Mi Park Jinhee Kim Sangeun Jeon Dong Hwan Kim Young-Eui Kim Joo Chan Lee Somyoung Im Yejin Jo Ji-Young Min Hanbyeul Lee Minjoo Yeom Sang-Hyuk Seok Da In On Hyuna Noh Jun-Won Yun Jun Won Park Daesub Song Je Kyung Seong Kyung-Ch Source Type: research
Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay
Antiviral Res. 2022 Nov 23:105473. doi: 10.1016/j.antiviral.2022.105473. Online ahead of print.ABSTRACTTo identify potent antiviral compounds, we introduced a high-throughput screen platform that can rapidly classify hit compounds according to their target. In our platform, we performed a compound screen using a lentivirus-based pseudovirus presenting a spike protein of coronavirus, and we evaluated the hit compounds using an amplified luminescence proximity homogeneous assay (alpha) test with purified host receptor protein and the receptor binding domain of the viral spike. With our screen platform, we were able to identi...
Source: Cell Research - November 26, 2022 Category: Cytology Authors: Kwiwan Jeong JuOae Chang Sun-Mi Park Jinhee Kim Sangeun Jeon Dong Hwan Kim Young-Eui Kim Joo Chan Lee Somyoung Im Yejin Jo Ji-Young Min Hanbyeul Lee Minjoo Yeom Sang-Hyuk Seok Da In On Hyuna Noh Jun-Won Yun Jun Won Park Daesub Song Je Kyung Seong Kyung-Ch Source Type: research
Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay
Antiviral Res. 2022 Nov 23:105473. doi: 10.1016/j.antiviral.2022.105473. Online ahead of print.ABSTRACTTo identify potent antiviral compounds, we introduced a high-throughput screen platform that can rapidly classify hit compounds according to their target. In our platform, we performed a compound screen using a lentivirus-based pseudovirus presenting a spike protein of coronavirus, and we evaluated the hit compounds using an amplified luminescence proximity homogeneous assay (alpha) test with purified host receptor protein and the receptor binding domain of the viral spike. With our screen platform, we were able to identi...
Source: Cancer Control - November 26, 2022 Category: Cancer & Oncology Authors: Kwiwan Jeong JuOae Chang Sun-Mi Park Jinhee Kim Sangeun Jeon Dong Hwan Kim Young-Eui Kim Joo Chan Lee Somyoung Im Yejin Jo Ji-Young Min Hanbyeul Lee Minjoo Yeom Sang-Hyuk Seok Da In On Hyuna Noh Jun-Won Yun Jun Won Park Daesub Song Je Kyung Seong Kyung-Ch Source Type: research
